Cite
HARVARD Citation
Borthakur, G. et al. (2016). Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies. Cancer. 122 (12), pp. 1871-1879. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Borthakur, G. et al. (2016). Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies. Cancer. 122 (12), pp. 1871-1879. [Online].